0.000USD0.000Pre-market 07/24, 09:30 (ET)
123.86BMarket Cap
17.22P/E TTM
Key Figures
60.720Open
62.045High
7.62MVolume
17.22P/E TTM
9.77P/E Dynamic
2.500Dividend TTM
0.38%Turnover Ratio
60.760Prev. Close
60.450Low
226.51MTurnover
LossP/E Static
6.70P/B
4.06%Div Yield TTM
8.13%ROA
62.88652wk High
0.81Volume Ratio
-8.95BNet Profit
2.01BShares
3.5723EPS TTM
0.24Beta
38.84%ROE
42.52052wk Low
2.63%Amplitude
66.53%Gross Margin
123.86BMarket Cap
7.40Reward/Risk
1.42%Risk Rate
Currency: USD Updated: 2026-07-23 Key Insights
Bristol-Myers Squibb Co's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 38 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 63.10.In the medium term, the stock price is expected to remain stable.Despite a good stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Bristol-Myers Squibb Co's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Bristol-Myers Squibb Co Highlights
StrengthsRisks
Bristol-Myers Squibb Co News
Earnings Forecast
Strong Buy
Buy
Hold
Sell
Strong Sell
Bristol-Myers Squibb Co
BMY
31
Indicators
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Bristol-Myers Squibb Co Info
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
Ticker SymbolBMY
CompanyBristol-Myers Squibb Co
CEOBoerner (Christopher S)
Websitehttps://www.bms.com
Shareholders
FAQs
What is the current price of Bristol-Myers Squibb Co (BMY)?
The current price of Bristol-Myers Squibb Co (BMY) is 61.53.
What is the symbol of Bristol-Myers Squibb Co?
The ticker symbol of Bristol-Myers Squibb Co is BMY.
What is the 52-week high of Bristol-Myers Squibb Co?
The 52-week high of Bristol-Myers Squibb Co is 62.89.
What is the 52-week low of Bristol-Myers Squibb Co?
The 52-week low of Bristol-Myers Squibb Co is 42.52.
What is the market capitalization of Bristol-Myers Squibb Co?
The market capitalization of Bristol-Myers Squibb Co is 123.86B.
Is Bristol-Myers Squibb Co (BMY) currently rated as Buy, Hold, or Sell?
According to analysts, Bristol-Myers Squibb Co (BMY) has an overall rating of signal_hold, with a price target of 63.10.
What is the Earnings Per Share (EPS TTM) of Bristol-Myers Squibb Co (BMY)?
The Earnings Per Share (EPS TTM) of Bristol-Myers Squibb Co (BMY) is 3.47.
